ADC (antibody-drug conjugate) has emerged as a promising class of anti-cancer drugs, with over a dozen ADC drugs currently approved for the treatment of various types of cancer patients. Traditional ADCs utilizeRead More…
Optimization Strategies for Dose Adjustment Due to the dose-dependent nature of adverse reactions in ADC therapies, optimizing safety can be achieved through dose adjustment strategies. These include setting dose limits, maximum treatmentRead More…
In recent years, the development of antibody-drug conjugate (ADC) therapies has flourished, leading to significant advancements in treating solid tumors. The FDA has approved six solid tumor ADCs so far—Sacituzumab govitecan (SG),Read More…
ADC has established a solid position in the oncology pharmacopoeia. Over 1,500 clinical trials of ADCs are listed on clinicaltrials.gov, and an increasing number of drugs are entering clinical trials. It canRead More…
Like most drugs, the development interruption of ADCs is typically due to a lack of efficacy, safety issues, commercial considerations, or a combination of these factors. Since 2000, among the 97 ADCsRead More…
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…
Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…
There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…
Bayer and Bicycle Therapeutics announced a strategic partnership agreement to develop, manufacture and commercialize targeted radiation conjugate drugs in the field of oncology using Bicycle Therapeutics’s synthetic peptide technology. Targeted radiotherapy isRead More…
Recently, Pfizer announced that it would buy Seagen for $229 a share in cash, for a total price of about $43 billion. According to the company’s website, Seagen currently has three ADCRead More…